Chloroacetyl chloride (CICH₂COCI)

Information and recommendations for paramedics and doctors at the site

- Before approaching the patient, the paramedics and doctors at the site must make sure that they do not risk exposing themselves to chloroacetyl chloride.
- Patients exposed only to chloroacetyl chloride gas do not pose a significant risk of secondary contamination. Patients whose clothing or skin is contaminated with liquid chloroacetyl chloride or solvents containing chloroacetyl chloride can secondarily contaminate rescue and medical personnel by direct contact or through off-gassing chloroacetyl chloride.
- Chloroacetyl chloride is a lacrimator and severe pulmonary irritants. Because of its hydrolysis in the alveoli, serious pulmonary effects and, therefore, symptoms of toxicity may be delayed up to 24 hours. Signs of pulmonary edema (shortness of breath, cyanosis, expectoration, cough) may appear hours after toxic exposures.
- There is no antidote to be administered to counteract the effects of chloroacetyl chloride. Treatment consists of supportive measures.

1. Substance information	Chloroacetyl chloride (CICH ₂ COCI), CAS 79-04-9 Synonyms: chloroacetic chloride, CAC Chloroacetyl chloride is a colorless, water-white liquid at room temperature with a melting point of -22 °C and a boiling point of 106°C. It has a sharp and pungent odor. Chloroacetyl chloride is hydrolyzed slowly by moisture to form chloroacetic acid and hydrochloric acid.
	Chloroacetyl chlorides are used as an intermediate in the manufacture of many chemicals including adrenalin, diazepam, chloroacetophenone, chloroacetate esters and chloroacetic anhydride.
2. Routes of exposure	
Inhalation	Most exposures occur by inhalation or by skin/eye contact. Chloroacetyl chloride's odor may provide insufficient warning of hazardous exposure that can occur even at low concentrations. Chloroacetyl chloride is heavier than air and may travel along the ground.
Skin/eye contact	Chloroacetyl chloride can cause irritation and burns of the skin and the eyes. Dermal absorption may occur.
Ingestion	Accidental ingestion of chloroacetyl chloride may occur and may cause irritation of the mouth, throat and stomach.
3. Acute health effects	Chloroacetyl chloride exposure usually causes skin, eye, nose, throat, and pulmonary irritation. Irritating effects immediately after exposure might be severe and delayed pulmonary damage, primarily edema, may occur as late as 24 hours after exposure. Chloroacetyl chloride poisoning may cause respiratory and cardiovascular failure. If the skin is wet or moist, contact with chloroacetyl chloride gas can cause irritation and redness of the skin. High gas concentrations may cause tearing and conjunctival erythema of the eye. Eye contact with liquid chloroacetyl chloride may result in clouding of the eye surface and delayed perforation.

Dose-effect relationships		Dose-effect relationships are as follows:	
Chloroacetyl chloride		Effect	
0.023 ppm 0.05 ppm 0.15 ppm 0.05 ppm 0.5 ppm 10 ppm	- - -	odor barely detectable 8 hr time weighted average (TWA) (ACGIH) 15 min short term exposure limit (STEL) (ACGIH) ERPG-1 (AIHA) ERPG-2 (AIHA) ERPG-3 (AIHA)	

The **TWA** is the concentration for a conventional 8-hour workday and a 40-hour workweek to which it is believed that nearly all workers may repeatedly be exposed to, day after day, without adverse effects. **ERPG-1** is the maximum airborne concentration below which it is believed that nearly all individuals could be exposed for up to 1 hour without experiencing other than mild transient health effects or perceiving a clearly defined, objectionable odor. **ERPG-2** is the maximum airborne concentration below which it is believed that nearly all individuals could be exposed for up to 1 hour without experiencing or developing irreversible or other serious health effects or symptoms which could impair an individual's ability to take protective action. **ERPG-3** is the maximum airborne concentration below which it is believed that nearly all individuals could be exposed for up to 1 hour without experiencing or developing irreversible or other serious health effects or symptoms which could impair an individual's ability to take protective action. **ERPG-3** is the maximum airborne concentration below which it is believed that nearly all individuals could be exposed for up to 1 hour without experiencing or developing life-threatening health effects.

4. Actions

A. Actions Rescuer self-protection	In response situations that involve exposure to potentially unsafe levels of chloroacetyl chloride (see below), pressure-demand, self- contained breathing apparatus and chemical-protective clothing shall be worn. Patients exposed only to chloroacetyl chloride gas do not pose a significant risk of secondary contamination. Patients whose clothing or skin is contaminated with liquid chloroacetyl chloride or solvents containing Chloroacetyl chloride can secondarily contaminate other people by direct contact or through off-gassing chloroacetyl chloride.
Patient recovery	Patients should be removed from the contaminated zone immediately. Patients who are unable to walk may be removed on backboards or stretchers; if these are not available, carefully remove/transport patients with appropriate action to a safe zone, taking into account your self- protection Immediate priorities must follow the "A, B, C's" (Airway, Breathing, Circulation) of resuscitation.
Decontamination	Patients exposed only to chloroacetyl chloride gas who have no evidence of skin or eye irritation do not need decontamination. All others require decontamination.
	Patients who are able and cooperative may assist with their own decontamination. If the exposure involves liquid chloroacetyl chloride or solvents containing chloroacetyl chloride and if clothing is contaminated, remove and double-bag the clothing.
	Assure that exposed skin and hair have been flushed with plain water for at least 20 minutes. If not, continue flushing during other basic care and transport. Protect eyes during flushing of skin and hair. Assure that exposed or irritated eyes have been irrigated with plain water or saline for at least 20 minutes. If not, continue eye irrigation during other basic care and transport. Remove contact lenses if present and easily removable without additional trauma to the eye.
Initial treatment	Therapy will be empiric; there is no antidote to be administered to counteract the effects of chloroacetyl chloride. The following measures are recommended if the exposure is ERPG- 2 or above, if symptoms, e. g. eye irritation or pulmonary symptoms have developed, or if no exposure can be estimated but exposure has possibly occurred:

- Administration of oxygen
- Administration of 8 puffs of beclomethasone (800 µg beclomethasone dipropionate) from a metered dose inhaler.

Patients with severe clinical respiratory symptoms (e.g. bronchospasms, stridor) should be treated as follows: a) Nebulization of adrenaline (epinephrine): 2 mg adrenaline (2 ml) with 3 ml NaCl 0.9% and inhale through a nebulizer mask.

b) Administration of a ß2-selective adrenoceptor agonist, e.g., four strokes of terbutaline or salbutamol or fenoterol (one stroke usually contains 0.25 mg of terbutaline sulfate; or 0.1 mg of salbutamol; or 0.2 mg of fenoterol); this may be repeated once after 10 minutes. Alternatively, 2.5 mg salbutamol and 0.5 mg atrovent may be administered by nebulizer mask.

If inhalation is not possible, administration of terbutaline sulfate (0.25 mg to 0.5 mg) subcutaneously or salbutamol (0.2 mg to 0.4 mg over 15 minutes) intravenously.

c) Intravenous administration of 250 mg methylprednisolone (or equivalent steroid dose).

Patients with clinical signs of a toxic lung edema (e.g. foamy sputum, wet crackles) should be treated as follows:

- a) Start CPAP-therapy (Continuous Positive Airway Pressure Ventilation).
- b) Intravenous administration of 1000 mg methylprednisolone (or an equivalent steroid dose) is recommended.

Intubation of the trachea or an alternative airway management should be considered in cases of respiratory compromise. When the patient's condition precludes this, consider cricothyrotomy if equipped and trained to do so.

Note: Efficacy of corticosteroid administration has not yet been proven in controlled clinical studies.

Patients exposed to a concentration of 10 ppm or greater (depending on time exposed) and patients without available exposure measurements but suspected of being exposed to concentrations of 10 ppm or greater (depending on time exposed) should be transferred to a hospital/emergency department.

If chloroacetyl chloride were in contact with the skin, chemical burns may result; treat as thermal burns: adequate fluid resuscitation and administration of analgesics, maintenance of the body temperature, covering of the burn with a sterile pad or clean sheet.

After eye exposure, chemical burns may result; treat as thermal burns. Immediately consult an ophthalmologist.

Note: Any facial exposure to liquid chloroacetyl chloride should be considered as a serious exposure.

Patients with an exposure of ERPG- 2 or above and patients without available exposure measurements but suspected of being exposed to an exposure of ERPG- 2 or above should be transported to a hospital/emergency department.

Patients with an exposure of **less than ERPG-2** as well as patients who have a **normal clinical examination and no signs or symptoms**

of toxicity may be discharged after an appropriate observation period in the following circumstances:

- a) The evaluating physician is experienced in the evaluation of individuals with chloroacetyl chloride exposure.
- b) Information and recommendations for patients with follow-up instructions are provided verbally and in writing.
- c) The physician is comfortable that the patient understands the health effects of chloroacetyl chloride and the provided follow-up instructions.
- d) Site medical is notified, so that the patient may be contacted at regular intervals in the 24-hour period following release.
- e) Heavy physical work should be precluded for 24 hours.
- f) Exposure to cigarette smoke should be avoided for 72 hours; the smoke may worsen the condition of the lungs.

In this document BASF has made a diligent effort to ensure the accuracy and currency of the information presented but makes no claim that the document comprehensively addresses all possible situations related to this topic. This document is intended as an additional resource for paramedics and doctors at the site in assessing the condition and managing the treatment of patients exposed to chloroacetyl chloride. It is not, however, a substitute for the professional judgement of a paramedic or a doctor and must be interpreted in the light of specific information regarding the patient available to such a paramedic or doctor and in conjunction with other sources of authority.

BASF SE

Corporate Health Management Carl-Bosch-Straße 38 67056 Ludwigshafen Germany BASF Corporation Medical Department 100 Park Avenue Florham Park, NJ 07932 USA

Reviewed: 2022 Code: E039-003